RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A patient preference study on risk thresholds to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma
Parikh, N., Girvan, A., Coulter, J., Gable, J., Poon, J., Kim, S., Chatterjee, A., & Boeri, M. (2021). A patient preference study on risk thresholds to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma. Annals of Oncology, 32(Suppl 3), S121-S122. https://doi.org/10.1016/j.annonc.2021.05.127
Abstract #P-72 ESMO 23rd World Congress on Gastrointestinal Cancer
There are various available second-line (2L) systemic treatments for unresectable hepatocellular carcinoma (HCC) utilizing different route of administration (eg, tablets and intravenous [IV] infusions) and having different safety profiles. Therefore, patient preferences should be considered in treatment decisions. However, there are insufficient data regarding patient preferences in the real-world setting in the US. The objectives of this study were to determine patients’ preferences for mode of administration and risk of adverse events (AEs) for regorafenib (4 tablets once daily [QD]) and ramucirumab (once in 2 weeks [Q2W] IV for 30/60 minutes) with similar efficacy profile but different AE profiles, and to determine the proportion of patients who preferred ramucirumab over regorafenib.